Our retrospective study of 827 patients with mutations in the GLA gene responsible for Fabry disease suggests that studies of α-galactosidase A activity and blood LysoGb3 dosage in female subjects are not reliable and therefore cannot be used as the first diagnostic test for diagnostic confirmation, nor for the screening of newborns. The gene discussed is GLA; the disease is Fabry disease.